Discussion
A single infusion of Allogene Therapeutics‘ cell therapy ALLO-329 was followed by clinically meaningful improvements in skin scores in eight of 10 people with skin-predominant systemic sclerosis (SSc), a hard-to-treat autoimmune disease. The findings come from an ongoing Phase 1 clinical trial called RESOLUTION (NCT07085104), which is…